Severity of Epstein-Barr Virus (EBV)-induced infectious mononucleosis (IM) correlates with the frequency of crossreactive influenza A virus-M1 and EBV-BMLF-1-specific CD8 T cells (105.48)

التفاصيل البيبلوغرافية
العنوان: Severity of Epstein-Barr Virus (EBV)-induced infectious mononucleosis (IM) correlates with the frequency of crossreactive influenza A virus-M1 and EBV-BMLF-1-specific CD8 T cells (105.48)
المؤلفون: Liisa Selin, Levi Watkin, Katherine Luzuriaga, Nuray Aslan
المصدر: The Journal of Immunology. 188:105.48-105.48
بيانات النشر: The American Association of Immunologists, 2012.
سنة النشر: 2012
مصطلحات موضوعية: Immunology, Immunology and Allergy
الوصف: During EBV-associated IM influenza A-specific crossreactive memory T cells are activated and play a role in disease severity. In HLA-A2+ IM patients, influenza M158 (IAV-M1)-specific CD8 memory T cell responses cross-reacted with two different EBV lytic epitopes, BMLF-1280 (17/29) and BRLF-1190 (19/20). Furthermore, 11/22 IM patients demonstrated some intra-viral cross-reactivity between EBV-BRLF1 and -BMLF1 responses. Disease severity of IM did not correlate with viral load, but instead directly correlated with significantly increased frequencies of crossreactive IAV-M1/EBV-BMLF-1-specific CD8 cells, as well as IAV-M1, EBV-BMLF-1 specific CD8 cells, but not BRLF1 responses. When severity of IM was scored and patients were assigned to either mild or severe groups, disease severity correlated with specific TCR Vb usage in all three tetramer-positive populations suggesting that TcR selection is driving disease outcome. Consistent with IAV-M1 and EBV-BMLF1 responses driving increased immunopathology was the observation that patients with severe disease had significantly more IAV-M1 and EBV-BMLF1 cells producing IFNg/MIP1-b in response to antigen as compared to patients with mild disease. These results suggest that T cell crossreactivity can impact T cell selection and function and ultimately disease outcome. Insights on these issues are important for the intelligent design of vaccines and to develop effect therapeutic interventions for virally induced disease.
تدمد: 1550-6606
0022-1767
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::bd4ac5eeb2b9b3157816fc1fb49a3f69
https://doi.org/10.4049/jimmunol.188.supp.105.48
رقم الأكسشن: edsair.doi...........bd4ac5eeb2b9b3157816fc1fb49a3f69
قاعدة البيانات: OpenAIRE